Literature DB >> 26707653

Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.

Marissa D Friedman1, Mario Lacouture2, Chau Dang3.   

Abstract

Entities:  

Keywords:  Adjuvant; HER2+; Lapatinib; Rash; Toxicity

Mesh：

Substances：

Year:  2015        PMID： 26707653      PMCID： PMC5599140          DOI： 10.1016/j.clbc.2015.11.001

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN： 1526-8209            Impact factor:   3.225


× No keyword cloud information.
  25 in total

1.  Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Authors:  Frances M Boyle; Ian E Smith; Joyce O'Shaughnessy; Bent Ejlertsen; Aman U Buzdar; Pierre Fumoleau; William Gradishar; Miguel Martin; Beverly Moy; Martine Piccart-Gebhart; Kathleen I Pritchard; Deborah Lindquist; Mayur Amonkar; Yingjie Huang; Erica Rappold; Lisa S Williams; Jing Wang-Silvanto; Tomomi Kaneko; Dianne M Finkelstein; Paul E Goss
Journal:  Eur J Cancer       Date:  2015-03-06       Impact factor: 9.162

Review 2.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.

Authors:  Jenny C Hu; Parrish Sadeghi; Lauren C Pinter-Brown; Sharona Yashar; Melvin W Chiu
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

3.  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

Authors:  Kimberly L Blackwell; Harold J Burstein; Anna Maria Storniolo; Hope S Rugo; George Sledge; Gursel Aktan; Catherine Ellis; Allison Florance; Svetislava Vukelja; Joachim Bischoff; José Baselga; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

4.  Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

Authors:  Angelo Di Leo; Henry L Gomez; Zeba Aziz; Zanete Zvirbule; Jose Bines; Michael C Arbushites; Stephanie F Guerrera; Maria Koehler; Cristina Oliva; Steven H Stein; Lisa S Williams; Judy Dering; Richard S Finn; Michael F Press
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

5.  Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.

Authors:  Aminah Jatoi; Erin M Green; Kendrith M Rowland; Daniel J Sargent; Steven R Alberts
Journal:  Oncology       Date:  2009-07-22       Impact factor: 2.935

Review 6.  Analysis of dermatologic events in patients with cancer treated with lapatinib.

Authors:  M E Lacouture; S M Laabs; M Koehler; R W Sweetman; A J Preston; A Di Leo; H L Gomez; V M Salazar; J A Byrne; K M Koch; K L Blackwell
Journal:  Breast Cancer Res Treat       Date:  2008-07-04       Impact factor: 4.872

7.  Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

Authors:  Zhongzhen Guan; Binghe Xu; Michelle L DeSilvio; Zhenzhou Shen; Wichit Arpornwirat; Zhongsheng Tong; Vicharn Lorvidhaya; Zefei Jiang; Junlan Yang; Anatoly Makhson; Wai Lim Leung; Mark W Russo; Beth Newstat; Li Wang; George Chen; Cristina Oliva; Henry Gomez
Journal:  J Clin Oncol       Date:  2013-03-18       Impact factor: 44.544

8.  Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer.

Authors:  Ciara C O'Sullivan; Karen L Smith
Journal:  Curr Breast Cancer Rep       Date:  2014-09-01

Review 9.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Authors:  Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-06-01       Impact factor: 3.603

10.  Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.

Authors:  George Dranitsaris; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2014-09-13       Impact factor: 4.872
View more
  1 in total

1.  Protein Binding of Lapatinib and Its N- and O-Dealkylated Metabolites Interrogated by Fluorescence, Ultrafast Spectroscopy and Molecular Dynamics Simulations.

Authors:  Inmaculada Andreu; Emilio Lence; Concepción González-Bello; Cristobalina Mayorga; M Consuelo Cuquerella; Ignacio Vayá; Miguel A Miranda
Journal:  Front Pharmacol       Date:  2020-10-30       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.